Belcorp: Supporting our consultants is vital to our success

Bert Taube and Dr Robert Brammer, Versant

Smart grids are a vital element of the future energy landscape. We hear a lot about the technology and infrastructure developments, but the big challenge for system operators is ‘big data’: how to make use of the information gathered. Bert Taube and Dr Robert Brammer discuss the different factors at play, and Versant’s extensive experience in the power industry and excellent foundations for targeting advanced developments.

Dr Khalid Klefeekh Al Hajri, Chairman and CEO, Qatar Solar Technologies

Qatar has committed to generating 1.8 gigawatts of solar power by 2014, and meet 20 percent of its energy needs with solar in the future. Qatar Solar Technologies – a joint venture between Qatar Foundation (70 percent), SolarWorld AG (29 percent) and the Qatar Development Bank (1 percent) – will be central to achieving this. Chairman and CEO Dr Khalid Klefeekh Al Hajri discusses the development of QSTech’s polysilicon plant, and explains how important the company is to the Qatar National Vision.

Alejandro Weinstein, CEO, CFR Pharmaceuticals

CFR Pharmaceuticals is a speciality pharmaceuticals group, operating numerous divisions of highly specialised staff in the areas of women’s health, neurology, bioscience and more. Alejandro Weinstein explains how the company’s huge network of representatives helps it bring the latest innovations to front-line healthcare professionals, outlines its joint ventures with prestigious research institutes, and discusses its highly successful 2011 IPO.

Dr Walton Li, Chairman and Medical Superintendent, Hong Kong Sanatorium and Hospital

Hong Kong’s healthcare – a free-of-charge public system complemented by a high-quality private sector – is the envy of many countries. But as the population ages and increases, the public side is struggling and the private side is having to turn patients away. Dr Walton Li explains the need for expansion in the private sector, and discusses how Hong Kong Sanatorium and Hospital attracts the finest doctors, nurses and support staff with its excellent training programmes and cutting-edge technology.

Sabrina Schütz-Oberländer, Managing Director, EAK (Made in Carinthia)

Despite a drop in forecast growth, Eastern Europe remains a key market, and businesses need to access it in a safe and sustainable way. Sabrina Schütz-Oberländer explains Carinthia’s advantage as a logistic hub “at the heart of New Europe,” and outlines Made in Carinthia’s mission to act as a centre of innovation in the region, attracting foreign investment with specialist services and incentives.

Cheryl Packwood, CEO, Business Bermuda

Bermuda has a global reputation as a top place to do business. It is the number one reinsurance jurisdiction in the world, and is well known for its for fund and asset managers. Business Bermuda is the membership organisation dedicated to facilitating companies’ entry to the country; Cheryl Packwood tells The New Economy how it can help business owners and investors form vital partnerships.

Best Sustainable Banking Group in Portugal, 2010 and 2011

Caixa Geral de Depositos is not only a cornerstone of the Portuguese economy, but a model of sustainability – financially, socially, and environmentally.
The New Economy visits CGD’s Lisbon headquarters to discover exactly how the bank has become such a shining example of responsible banking.

Dionysios Xenos, General Manager, med eHealthCY

Rapid socio-economic development in southeast Europe has put significant pressure on countries’ healthcare systems, at a time when costs are escalating. Dionysios Xenos outlines how med eHealthCY can help health organisations become more efficient through training in best practices and IT; and how countries can benefit from the company’s eHealth Network software.

Dimitri Dimitriou, CEO, Immupharma

Immupharma’s specialised treatment for those suffering from the chronic disease Lupus has been cleared by the US FDA to move into Phase 3 of testing, with fast track approval once passed. Dimitri Dimitriou explains the different phases of drug development, the strategic importance of Immupharma’s partnership with the French National Research Institution, and the ongoing challenge for the pharmaceutical industry: patent expiry.